Spineart Releases SCARLET AC-Ti Secured Anterior Cervical Cage

Spineart has launched its SCARLET AC-Ti secured anterior cervical cage in the United States.

Following U.S. Food and Drug Administration 510(k) clearance last May, SCARLET AC-Ti has been extensively evaluated by clinical experts.

“With SCARLET AC-Ti, I have observed consistent performance, reliable standalone stability—with no instances of postoperative dysphagia,” said Zakhria Belasher, M.D.,* (Insight Surgical Hospital), who has implanted more than 50 SCARLET AC-Ti cervical cages. “Its intuitive design, porous titanium structure, and optimized screw angulation promotes early fusion while enhancing patient recovery and surgical efficiency, making it a seamless and trusted component of my anterior cervical fusion practice.”

SCARLET AC-Ti builds on a decade of experience with the SCARLET system and uses the company’s Ti-LIFE technology, a proprietary additive manufacturing process, providing a porous structure that closely mimics the trabecular bone structure. The secured anterior cervical cage is known for its redefined anatomical shape, integrated screw guides and anti-backout mechanism.

The SCARLET AC-T system combines in one implant an interbody device and cervical plate. The implant’s profile allows for an anatomical fit between endplates and offers a 7-degree lordotic option. The screws help stabilize the cage; the micro-threaded and has conical-shaped head secures the screw by controlling the potential risk of expulsion once locked into the cage.

“With SCARLET AC-Ti, we’re bringing an exciting new advancement to the ACDF segment in the U.S., reinforcing our ongoing commitment to innovation. Following the highly promising results from the initial release phase, we are thrilled to now make this latest technology available to more surgeons,” Spineart Chief Commercial Officer Alessia Erlingher stated.

Spineart is a global company developing spine surgery technologies for surgeons and hospitals. The company was awarded the “Prix de l’Economie Genevoise 2022” for its contribution to technological and scientific innovations, commercial activities, job creations and ESG principles.

*Dr. Belasher is a Spineart paid consultant.